Inhaled insulin using AERx® insulin Diabetes Management System (AERx® iDMS)

Expert Opinion on Investigational Drugs

Volumn 16, Issue 10, 2007, Pages 1673-1681

  Mudaliar, Sunder ^a  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

Efficacy; Inhaled insulin; Pharmacodynamics; Pharmacokinetics; Safety; Type 1 diabetes; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ANTIBODY; INSULIN ASPART; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; PLACEBO; ANTIDIABETIC AGENT;

AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL TRIAL; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIABETIC MICROANGIOPATHY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EVENING DOSAGE; EXERCISE; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INHALER; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LUNG DIFFUSION CAPACITY; LUNG FUNCTION TEST; MAXIMUM PLASMA CONCENTRATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SINGLE DRUG DOSE; SMOKING; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; INHALATIONAL DRUG ADMINISTRATION; REVIEW; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; TREATMENT OUTCOME;

EID: 35248871207     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.10.1673     Document Type: Article

References (25)

1. UKPDS: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). UK prospective diabetes study (UKPDS) group. Lancet (1998) 352:837-853.
2. DCCT: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N. Engl. J. Med. (1993) 329:977-986.
3. PEYROT M, RUBIN RR, LAURITZEN T et al.: Resistance to insul therapy among patients and providers: results of the cross-national diabetes attitudes, wishes, and needs (DAWN) study. Diabetes Care (2005) 28:2673-2679.
4. POLONSKY WH, FISHER L, GUZMAN S, VILLA-CABALLERO L, EDELMAN SV: Psychological insulin resistance in patients with Type 2 diabetes the scope of the problem. Diabetes Care (2005) 28:2543-2545.
5. MCMAHON GT, ARKY RA: Inhaled insulin for diabetes mellitus. N. Engl. J. Med. (2007) 356:497-502.
6. THIPPHAWONG J, OTULANA B, CLAUSON P, OKIKAWA J, FARR SJ: Pulmonary insulin administration using the AERx® insulin diabetes system. Diabetes Technol. Ther. (2002) 4:499-504.
7. BRUNNER GA, BALENT B, ELLMERER M et al.: Dose-response relation of liquid aerosol inhaled insulin in Type I diabetic patients. Diabetologia (2001) 44:305-308.
8. GONDA I, SCHUSTER JA, RUBSAMEN RM, LLOYD P, CIPOLLA D, FARR SJ: Inhalation delivery systems with compliance and disease management capabilities. J. Control. Rel. (1998) 53:269-274.
9. FARR SJ, MCELDUFF A, MATHER LE et al.: Pulmonary insulin administration using the AERx® system: physiological and physicochemical factors influencing insulin effectiveness in healthy fasting subjects. Diabetes Technol. Ther. (2000) 2:185-197.
10. AN B, REINHARDT RR: Effects of different durations of breath holding after inhalation of insulin using the AERx® insulin diabetes management system. Clin. Ther. (2003) 25:2233-2244.
11. KAPITZA C, HOMPESCH M, SCHARLING B, HEISET: Intrasubject variability of inhaled insulin in Type 1 diabetes: a comparison with subcutaneous insulin. Diabetes Technol. Ther. (2004) 6:466-472.
12. ROSENSTOCK J: Management of Type 2 diabetes mellitus in the elderly: special considerations. Drugs Aging (2001) 18:31-44.
13. HENRY RR, MUDALIAR S, CHU N et al.: Young and elderly Type 2 diabetic patients inhaling insulin with the AERx® insulin diabetes management system: a pharmacokinetic and pharmacodynamic comparison. J. Clin. Pharmacol. (2003) 43:1228-1234.
14. HERMANSEN K, RONNEMAA T, PETERSEN AH, BELLAIRE S, ADAMSON U: Intensive therapy with inhaled insulin via the AERx® insulin diabetes management system: a 12-week proof-of-concept trial in patients with Type 2 diabetes. Diabetes Care (2004) 27:162-167.
15. MOSES R, LUNT H, BARTLEY P et al.: Preprandial inhaled human insulin via the AERx iDMS vs subcutaneous insulin aspart in type 1 diabetes. Diabet. Med. (2006) 23(Suppl. 4):338.
16. CRAMER JA, OKIKAWA J, BELLAIRE S, CLAUSON P: Compliance with inhaled insulin treatment using the AERx® iDMS insulin diabetes management system. Diabetes Technol. Ther. (2004) 6:800-807.
17. NORWOOD PDR, CEFALU W, YALE JF, ENGLAND R, RIESE R: Randomized study to characterize glycemic control and short-term pulmonary function in patients with Type 1 diabetes receiving inhaled human insulin (Exubera(R)). J. Clin. Endocrinol. Metab. (2007) 92(6):2211-2214.
18. HENRY RR, MUDALIAR SR, HOWLAND WC III et al.: Inhaled insulin using the AERx® insulin diabetes management system in healthy and asthmatic subjects. Diabetes Care (2003) 26:764-769.
19. JONES JG, MINTY BD, LAWLER P, HULANDS G, CRAWLEY JC, VEALL N: Increased alveolar epithelial permeability in cigarette smokers. Lancet (1980) 1:66-68.
20. HIMMELMANN A, JENDLE J, MELLEN A, PETERSEN AH, DAHL UL, WOLLMER P: The impact of smoking on inhaled insulin. Diabetes Care (2003) 26:677-682.
21. WIASE S, CHIEN J, YEO K, RICHARDSON C: Smoking enhances absorption of insulin but reduces glucodynamic effects in individuals using the Lilly-Dura inhaled insulin system. Diabet. Med. (2006) 23:510-515.
22. MCELDUFF A, MATHER LE, KAM PC, CLAUSON P: Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx® insulin diabetes management system. Br. J. Clin. Pharmacol. (2005) 59:546-551.
23. PETERSEN AH, KOHLER G, KORSATKO S et al.: The effect of exercise on the absorption of inhaled human insulin via the AERx(R) iDMS in people with Type 1 diabetes. Diabetes Care (2007) (In Press).
24. FINEBERG SE, KAWABATA T, FINCO-KENT D, LIU C, KRASNER A: Antibody response to inhaled insulin in patients with Type 1 or Type 2 diabetes. An analysis of initial Phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J. Clin. Endocrinol. Metab. (2005) 90:3287-3294.
25. INHALED INSULIN (EXUBERA): Rapid report 01. Cologne, Germany: Institute for quality and efficiency in health care (2006).